News

The CHRONOS study highlights a 29% 12-month survival rate for third-line GI-aGvHD, underscoring an urgent need for standardized therapies after ruxolitinib failure.

Why is "chemotherapy" being phased out? MiKaela M. Olsen, DNP, APRN-CNS, AOCNS®, FAAN, joins Onc Nurse on Call to break down the new ASCO-ONS safety standards for oncology nurses.

The FDA has granted Fast Track designation to the FRα-targeting ADC ZW191 as a potential treatment for patients with for platinum-resistant ovarian cancer.

Anurag K. Agrawal, MD, of the American Cancer Society, discusses global oncology nursing challenges, including high patient ratios, hierarchy, and chemo safety.

Adagrasib shows efficacy in elderly patients with KRAS G12C-mutant NSCLC and an ECOG PS of 0-1, while those with a PS of 2 see limited survival benefit but QOL improvements.

Hardik Thakkar, MSPAS, PA-C, discusses the ways in which NPs and PAs can benefit from each other’s specialized training.

Calderasib, a potent KRAS G12C inhibitor, demonstrated improved outcomes in patients with metastatic NSCLC, especially when combined with pembrolizumab.

Explore phase 1 data for setidegrasib, a novel KRAS G12D-targeted protein degrader showing antitumor activity and manageable infusion-related reactions in patients with advanced NSCLC.

Natalia Neparidze, MD, discusses subcutaneous daratumumab safety, MRD as a clinical endpoint, and emerging therapies for multiple myeloma management.

The FDA approved the combination of relacorilant and nab-paclitaxel in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

A physician, physician assistant, and nurse practitioner share perspectives on integrative medicine in oncology.

Amber Altidor, NP, shares how oncology nurses can use teach-back methods and learning style assessments to improve patient education on medication toxicities.

Data presented at the annual APOS Conference revealed training and workflow issues in providing developmentally appropriate cancer care to AYA patients.

The FDA has granted traditional approval to nivolumab in cHL after autologous HSCT and brentuximab vedotin and after 3 or more lines of therapy.

The NCCN has added sacituzumab govitecan with pembrolizumab as a category 1 preferred regimen for patients with PD-L1–postive TNBC.

Data presented at the APOS Annual Conference highlighted sexual function issues and a web-based intervention for AYA cancer survivors.

Patients younger than 40 experience higher rates of CINV and more commonly use marijuana, diet changes, and other methods to manage symptoms.

Jamie S. Myers, PhD, RN, AOCNS, FAAN, shares insights from a career of oncology nursing research, including advice for those new to the field.

Radiation-induced heart damage in breast cancer is a growing clinical concern, yet biomarkers and preventive therapies remain lacking.

A multidisciplinary approach to care is key when addressing sexual health concerns among breast cancer survivors.

Mark S. Lin, MSN, FNP-BC, highlighted nursing considerations for breast reconstruction surgery in breast cancer.

Lillian Rodich, PA-C, MPH, stressed that nurses can take advantage of accessible and local integrative medicine resources to treat patients with cancer.

Don S. Dizon, MD, FACP, FASCO, shared insights on what pregnancy looks like with a breast cancer diagnosis and what those considering pregnancy should know.

Findings from real-world community clinics show favorable efficacy of trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer.

The FDA issued a complete response letter to retifanlimab due to inspection findings at a third-party facility.

Tazemetostat has been withdrawn from the market for all approved indications following safety data conveying secondary hematologic malignancy risk.

Samantha Shenoy, NP, MSN, provides nursing guidance on teclistamab/subcutaneous daratumumab’s second-line approval in multiple myeloma.

Patricia Jakel, MN, RN, AOCN, shares how personal and professional experience impact her view on testing even beyond what is recommended.